Eliem Therapeutics Provides ETX-810 Program Update

Author's Avatar
Aug 02, 2022

Phase 2a clinical trial of ETX-810 in lumbosacral radicular pain (LSRP) did not achieve the primary endpoint; ETX-810 program will be discontinued